2. Amyotrophic lateral sclerosis
508 clinical trials,   530 drugs   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways

Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04302870
(ClinicalTrials.gov)
February 27, 20204/3/2020Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised TrialMotor Neurone Disease - Systematic Multi-Arm Adaptive Randomised TrialMotor Neuron Disease, Amyotrophic Lateral SclerosisDrug: Memantine Hydrochloride Oral Solution;Drug: Trazodone Hydrochloride oral solution;Drug: Placebo oral solutionUniversity of EdinburghUniversity College, London;University of Warwick;NHS LothianRecruiting18 YearsN/AAll750Phase 2;Phase 3United Kingdom
2NCT02118727
(ClinicalTrials.gov)
November 7, 201815/4/2014Therapy in Amyotrophic Lateral Sclerosis (TAME)Multi-centered Double Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Memantine at 20 mg BID in Patients With ALSAmyotrophic Lateral Sclerosis;Frontal Temporal DementiaDrug: Memantine;Drug: Placebo (for Memantine)University of Kansas Medical CenterNULLRecruiting18 Years85 YearsAll90Phase 2United States
3EUCTR2007-002117-39-ES
(EUCTR)
31/01/200812/02/2008MEMANTINA (Ebixa X) PARA LA DISCAPACIDAD FUNCIONAL EN LA ESCLEROSIS LATERAL AMIOTRÓFICAMEMANTINE (Ebixa R) FOR FUNCTIONAL DISABILITY IN AMYOTROPHIC LATERAL SCLEROSIS . - MEDALSMEMANTINA (Ebixa X) PARA LA DISCAPACIDAD FUNCIONAL EN LA ESCLEROSIS LATERAL AMIOTRÓFICAMEMANTINE (Ebixa R) FOR FUNCTIONAL DISABILITY IN AMYOTROPHIC LATERAL SCLEROSIS . - MEDALS Esclerosis Lateral AmiotroficaAmyotrophic lateral Sclerosis
MedDRA version: 9.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Trade Name: EBIXA
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Jorge Matias-Guiu GuiaNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
140Spain
4NCT00409721
(ClinicalTrials.gov)
March 20078/12/2006The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS)A Randomized, Double-blind, Dose Ranging Study to Determine the Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Patients With ALSAmyotrophic Lateral SclerosisDrug: MemantineUniversity of AlbertaALS AssociationCompleted18 Years80 YearsBoth42Phase 2Canada
5NCT00353665
(ClinicalTrials.gov)
July 200518/7/2006Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS)Phase 2-3 - Memantine for Disability in Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisDrug: Memantine (Ebixa);Drug: riluzole;Drug: PlaceboUniversity of LisbonH. Lundbeck A/SCompleted20 Years75 YearsBoth63Phase 2;Phase 3Portugal
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01020331
(ClinicalTrials.gov)
June 200520/11/2009Memantine Therapy in Amyotrophic Lateral SclerosisPhase IIA Open Label Trial of Memantine in Combination With Riluzole (Customary Care) for the Treatment of ALSAmyotrophic Lateral SclerosisDrug: MemantinePhoenix Neurological Associates, LTDForest LaboratoriesCompleted18 Years85 YearsBoth20Phase 2United States